Pfizer (PFE), Protalix (PTX) UPLYSO Receives Approval in Brazil
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Brazilian Approval a Positive for Protalix (PLX) - Oppenheimer
March 19, 2013 9:46 AM EDTOppenheimer reiterated their Outperform rating and $7 price target Protalix BioTherapeutics (NYSE: PLX) after Uplys received approval from the Brazilian National Health Surveillance Agency for the treatment of adults with confirmed diagnosis of Type I Gaucher disease.
"The announcement is an expected incremental... More
